Aerpio Pharmaceuticals, Inc. ARPO
Set alert
At close
52-week range unavailable
- Open
- 2.22
- Prev close
- 2.20
- Mkt cap
- 104.85M
- Vol
- 826.01K
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 2.16
- High
- 2.30
- Forward P/E
- -1.21
- Beta
- 1.65
- Short ratio
- 1.81
- Inst. own
- 71.05%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 11, 2021
- 50-d avg
- 31.63
- 200-d avg
- 25.85
- 1y target
- 22.00
Key statistics
- Market cap
- 104.85M
- Enterprise value
- 69.00M
- Trailing P/E
- 0.00
- Forward P/E
- -1.21
- PEG ratio
- 0.00
- Price / book
- 2.96
- EPS (TTM)
- -0.405
- Beta
- 1.65
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -12.10M
- Total cash
- 36.82M
- Total debt
- 9.96K
- Return on equity
- -47.60%
- Shares outstanding
- 47.66M
- Short % of float
- 7.73%
- 50-day average
- 31.63
- 200-day average
- 25.85
Analyst view
Consensus: buy
- Strong buy0
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 11, 2021
Expected Aug 11, 2021. Consensus EPS estimate 0.00.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Aug 11, 2021 | Jun 1, 2021 | -0.40 | — | — | — |
| May 17, 2021 | Mar 1, 2021 | -0.09 | — | — | — |
| Mar 11, 2021 | Dec 1, 2020 | -0.13 | — | — | — |
| Nov 10, 2020 | Sep 1, 2020 | -0.14 | — | — | — |
| Aug 12, 2020 | Jun 1, 2020 | 0.27 | — | — | — |
| May 7, 2020 | Mar 1, 2020 | -0.09 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jul 8, 2021 | HC Wainwright & Co. | up | Neutral | Buy |
| Dec 14, 2020 | HC Wainwright & Co. | main | — | Neutral |
| Aug 13, 2020 | HC Wainwright & Co. | main | — | Neutral |
| Jun 25, 2020 | HC Wainwright & Co. | main | — | Neutral |
| Jun 12, 2019 | H.C. Wainwright | init | — | Neutral |
| Mar 19, 2019 | H.C. Wainwright | down | Buy | Neutral |
About Aerpio Pharmaceuticals, Inc.
Aerpio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing compounds that activate Tie2 for the treatment of ocular disease and vascular stabilization. The company's lead product candidate is razuprotafib, a small molecule inhibitor of vascular endothelial protein tyrosine phosphatase , which has completed phase IIb clinical trial for the treatment of non-proliferative diabetic retinopathy, as well as has completed phase II clinical trial for the treatment of patients with open angle glaucoma/ocular hypertension. It also develops ARP-1536, a humanized monoclonal antibody that is in preclinical development stage for the treatment of diabetic vascular complications, including nephropathy and diabetic macular edema; and bispecific antibody for the treatment for wet age-related macular degeneration and DME through intravitreal injection. Aerpio Pharmaceuticals, Inc. has a licensing and collaboration agreement with Gossamer Bio, Inc. for the development and commercialization of GB004, a selective stabilizer of hypoxia-inducible factor-1 alpha, which has completed Phase 1b clinical trial for the treatment of inflammatory bowel disease. The company is headquartered in Cincinnati, Ohio.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- aerpio.com
News
- The 6 Best Penny Stocks to Buy for September
- Top Penny Stocks to Buy? Here's 3 That Investors Are Watching
- Best Penny Stocks To Buy Right Now? 5 To Watch Before September
- Aerpio Reports Second Quarter 2021 Financial Results and Provides Business Update
- Penny Stocks to Buy Right Now? 4 For Your Late July Watchlist
- Hot Penny Stocks to Buy Now? 6 Reopening Stocks To Watch In July 2021
- Best Biotech Penny Stocks to Buy in July 2021? 6 For Your Watchlist
- INVESTIGATION ALERT: Halper Sadeh LLP Investigates ONEM, SYKE, NETE, CHMA, SOLY, ARPO; Shareholders are Encouraged to Contact the Firm
- Why Aerpio Shares Are Skyrocketing Today
- DBGI Stock: 13 Things to Know About Digital Brands as Shares Take Off Today
Your note
Sign in to keep a note on ARPO — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CASTELEIN CALEY M. M.D. | Director | Stock Award(Grant) | Jun 29, 2021 | 295,414 |
| COHEN CHERYL L | Director | Stock Award(Grant) | Jun 29, 2021 | 16,160 |
| DALAL ANUPAM | Director | Stock Award(Grant) | Jun 29, 2021 | 16,959 |
| DUGEL PRAVIN U | Director | Stock Award(Grant) | Jun 29, 2021 | 12,568 |
| GARDNER JOSEPH H | President | Purchase | Jul 9, 2019 | 603,019 |
| HOFFMAN STEPHEN J. M.D., PH.D. | Chief Executive Officer | Purchase | Nov 11, 2018 | 31,967 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Satter Management Company, LP | 27.71% | 11,243,670 | 19.00M | Jun 29, 2021 |
| Orbimed Advisors LLC. | 25.60% | 10,387,892 | 17.56M | Jun 29, 2021 |
| Avoro Capital Advisors LLC | 22.18% | 9,000,000 | 15.21M | Jun 29, 2021 |
| RA Capital Management, L.P. | 13.27% | 5,386,618 | 9.10M | Jun 29, 2021 |
| Renaissance Technologies, LLC | 12.74% | 5,168,694 | 8.74M | Jun 29, 2021 |
| Vanguard Group, Inc. (The) | 8.75% | 3,548,926 | 6.00M | Jun 29, 2021 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 6.39% | 2,594,930 | 3.35M | Mar 30, 2021 |
| Vanguard Extended Market Index Fund | 2.24% | 907,120 | 1.17M | Mar 30, 2021 |
| Price (T.Rowe) Extended Equity Market Index Fund | 1.25% | 507,400 | 654.55K | Mar 30, 2021 |
| Fidelity Extended Market Index Fund | 0.85% | 345,300 | 583.56K | Jun 29, 2021 |
| iShares Core S&P Total U.S. Stock Market ETF | 0.64% | 258,164 | 436.30K | Jun 29, 2021 |
| iShares Micro Cap ETF | 0.51% | 207,168 | 350.11K | Jun 29, 2021 |